Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nordic Immotech is a life science company specializing in the development and commercialization of natural immunomodulatory products and dietary supplements. The company's flagship product, Immulina, is a proprietary spirulina extract (LCEPEEN) developed in collaboration with the University of Mississippi's National Center for Natural Products Research. Immulina is a scientifically-validated supplement designed to enhance immune function by activating natural killer (NK) cells and monocytes. Originally established with operations in Denmark and Sweden, the company's Swedish subsidiary, Nordic Immotech Sweden AB, was acquired by the Humble Group in 2022. Nordic Immotech continues to leverage its research-driven approach to provide high-quality health solutions within the functional food and supplement sectors.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nordic Immotech Trading.